Medigama - Company finances
|
EUR
|
2019
From: 2019-01-03
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 28,541 | 61,719 | 103,354 | 117,972 | 353,204 | 517,568 | 810,994 |
| Profit before tax | 11,065 | 23,800 | 44,756 | 35,899 | 106,356 | 100,405 | 10,516 |
| Net profit | 10,512 | 22,489 | 42,455 | 34,078 | 90,206 | 85,192 | 7,565 |
| Equity | 10,512 | 10,666 | 18,210 | 14,301 | 42,733 | 63,856 | 20,708 |
| Liabilities | - | - | - | 16,386 | 137,522 | 58,202 | 81,839 |
| Non-current assets | 0 | 1,078 | 1,737 | 1,768 | 27,274 | 22,267 | 17,745 |
| Current assets | 13,568 | 12,135 | 27,533 | 28,919 | 152,981 | 99,791 | 84,802 |
| Total assets | 13,568 | 13,213 | 29,270 | 30,687 | 180,255 | 122,058 | 102,547 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 14,106 | 5,133 | - |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +116.2% | +67.5% | +14.1% | +199.4% | +46.5% | +56.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 77.5% | 170.2% | 145.0% | 111.1% | 50.0% | 69.8% | 7.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 210.8% | 233.1% | 238.3% | 211.1% | 133.4% | 36.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 36.8% | 36.4% | 41.1% | 28.9% | 25.5% | 16.5% | 0.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 38.8% | 38.6% | 43.3% | 30.4% | 30.1% | 19.4% | 1.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 1.1 | 3.2 | 0.9 | 4.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 72,009 | - | - | - | - | 810,994 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Medigama - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-03 | 2026-08-11 | 25.96 |
| 2026-08-01 | 2026-08-02 | 27.56 |
| 2026-07-27 | 2026-07-31 | 1.60 |
| 2026-07-23 | 2026-07-26 | 283.14 |
| 2026-07-19 | 2026-07-22 | 281.54 |
| 2026-07-16 | 2026-07-17 | 281.54 |
| 2026-06-16 | 2026-06-24 | 281.54 |
| 2026-05-17 | 2026-05-25 | 281.54 |
| 2024-05-15 | 2024-06-30 | 250.43 |
Medigama - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Medigama, MB (code 304979823) is a Small partnership engaged in the wholesale of pharmaceutical and medical goods. In 2025, the latest financial year, the company generated €811.0K in revenue, up 56.7% year on year and 129.6% over two years. However, profitability weakened sharply: net profit fell to €7.6K from €85.2K in 2024 and €90.2K in 2023, reducing the net margin to 0.9% from 16.5% and 25.5% in the prior years. This indicates that revenue growth was not matched by earnings growth in 2025. The balance sheet also contracted, with total assets decreasing to €102.5K from €122.1K in 2024 and €180.3K in 2023. Equity declined to €20.7K, while liabilities increased to €81.8K. Key ratios for 2025 show ROE of 36.5%, ROA of 7.4%, debt-to-equity of 3.95, and asset turnover of 7.91x. Revenue per employee was €811.0K, while profit per employee was €7.6K.